Chlormezanon

Chlormezanone

HCID 2717CAS 102818-66-6

Grundinformationen

Standard-SMILES
CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1
InChIKey
WEQAYVWKMWHEJO-UHFFFAOYSA-N
Summenformel
C11H12ClNO3S
Durchschnittliche Molmasse
273,74 g/mol
Monoisotopische Masse
273,02264192

Überblick

Chlormezanone is a 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions. It has a role as an anxiolytic drug, an antipsychotic agent and a muscle relaxant. It is a lactam, a sulfone, a 1,3-thiazine and a member of monochlorobenzenes.

Namen und Bezeichner

Bevorzugter Name
Chlormezanone
IUPAC
2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one
Lokaler Name
Chlormezanon
Englischer Name
Chlormezanone
Summenformel
C11H12ClNO3S
Molmasse
273.74

Namen und Synonyme

chlormezanone80-77-3ChlormethazanoneTrancopalChlormethazoneChlormezanonClormetazanoneClormetazonPhenaroldl-ChlormezanoneBanabinClorilax
Weitere Namen anzeigen
LobakRilaxAlinamMuskelwin4692FENAROLMio-Sed
MiorilaxRilansylRilaquilRilassolSupotranTanafolBisinaRexan

Datenbank-Bezeichner

CAS
102818-66-6、102818-67-7、80-77-3
PubChem CID
2717
DTXSID
DTXSID3022798
ChEMBL
CHEMBL1200714
ChEBI
CHEBI:3619
UNII
4BU37OM8KL、C14WB33Y0S、GP568V9G19
EC Number
201-307-4

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1,1
Polarare Oberfläche (TPSA)
62,8 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
1
Schwere Atome
17

Experimentelle und physikochemische Eigenschaften

LogP1.3
Color/FormCRYSTALS
Solubility · 3 Einträge

SOL (% WT/VOL) @ 25 °C: LESS THAN 0.25% IN WATER, LESS THAN 1.0% IN 95% ETHANOL

FREELY SOL IN CHLOROFORM; SLIGHTLY SOL IN DIETHYL ETHER; SPARINGLY SOL IN N-HEXANE

1.61e+00 g/L

Human Drugs · 3 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 3 Einträge

116.2-118.6

116.2-118.2 °C

116.2 °C

Physical DescriptionSolid

Physikochemische Eigenschaften

Schmelzpunkt
114 °C · 114 °C
Siedepunkt
534.5 · 534.5±50.0 °C(Predicted)
Dichte
1.2205 · 1.2205 (rough estimate)
Brechungsindex
1.63 · 1.6300 (estimate)
storage temp.
Sealed in dry,Room Temperature
Löslichkeit
Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 4 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Other Safety InformationIMAP assessments - 4H-1,3-Thiazin-4-one, 2-(4-chlorophenyl)tetrahydro-3-methyl-, 1,1-dioxide: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Interactions · 1 Eintrag

CHLORMEZANONE MAY LOWER TOLERANCE OF PATIENTS TO ALCOHOL...POSSIBLE ADDITIVE EFFECTS /WITH CHLORMEZANONE &/ CNS DEPRESSANTS SUCH AS ALCOHOL, PHENOTHIAZINES, BARBITURATES, NARCOTICS, OTHER PSYCHOTHERAPEUTIC AGENTS, & MONOAMINE OXIDASE INHIBITORS.

Toxicity Summary · 1 Eintrag

Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

Signs and SymptomsSymptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.
Human Toxicity Excerpts · 4 Einträge

...COMMONLY PRODUCE DROWSINESS, DIZZINESS, HEADACHE, BLURRED VISION, WEAKNESS, LETHARGY, ATAXIA, & NYSTAGMUS. NAUSEA, VOMITING, HEARTBURN, & ABDOMINAL DISTRESS...ESP AFTER LARGE ORAL DOES. ...SKIN RASH & PRURITUS &, RARELY, ANAPHYLACTOID REACTIONS & LEUKOPENIA. /CENTRALLY ACTING MUSCLE RELAXANTS/

INCIDENCE OF UNTOWARD REACTIONS IS ABOUT 3% & MINOR IN NATURE...MALAISE, EXCITEMENT... PETECHIAE, OR ECCHYMOSES SOMETIMES DEVELOP; LIVER DAMAGE...OR ANGIONEUROTIC EDEMA ARE RARE.

LETHARGY & FLUSHING HAVE BEEN OBSERVED & JAUNDICE HAS OCCURRED RARELY.

...ORAL TOXICITY LESS THAN MEPROBAMATE, ZOXAZOLAMINE, OR METHOCARBAMOL. ... IN CLINICAL TRIALS ONLY 2.3% OF 4653 PT HAS SIDE EFFECTS... OVERDOSAGE UP TO 10 G HAS NOT CAUSED DEATH. EVEN LARGE AMT PRODUCE ONLY MILD SIDE EFFECTS.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Chlormezanone

vMost-DILI-concern

8

Withdrawn

DOI:10.1016/j.drudis.2016.02.015

Sicherheitsdaten

hs_code
2934.99.4400
RTECS-Nr.
XJ1050000
Speicherklasse
11 - Combustible Solids
Giftige Stoffe Daten
80-77-3(Hazardous Substances Data)
Hazard Classifications
Acute Tox. 4 Oral

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

M - Musculo-skeletal system

QM - Musculo-skeletal system

PharmacodynamicsChlormezanone is a non-benzodiazepine muscle relaxant. It was discontinued worldwide in 1996 by its manufacturer due to confirmed serious and rare cutaneous reactions (toxic epidermal necrolysis).
Mechanism of Action · 3 Einträge

Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.

NEURONAL CONDUCTION, NEUROMUSCULAR TRANSMISSION, & MUSCLE EXCITABILITY ARE NOT DEPRESSED EXCEPT AFTER NEARLY LETHAL DOSES. PROMINENT EFFECT...IS TO DEPRESS SPINAL POLYSYNAPTIC REFLEXES PREFERENTIALLY OVER MONOSYNAPTIC REFLEXES. /CENTRALLY ACTING MUSCLE RELAXANTS/

IN ABSENCE OF DEFINITIVE STUDIES IT APPEARS REASONABLE TO ASCRIBE BENEFICIAL EFFECTS...TO THEIR SEDATIVE PROPERTIES. /CENTRALLY ACTING MUSCLE RELAXANTS/

Metabolism/Metabolites · 2 Einträge

CHLORMEZANONE...IS EXCRETED UNCHANGED IN HUMAN URINE & DOG BILE. FORMATION OF 4-CHLOROHIPPURIC ACID, MAJOR URINARY METABOLITE IN MAN, INVOLVES NON-ENZYMIC HYDROLYSIS, FOLLOWED BY OXIDATION & CONJUGATION OF 4-CHLOROBENZALDEHYDE PRODUCT OF HYDROLYSIS.

(14)C-CHLORMEZANONE, METABOLITES IN URINE OF RATS & MICE WERE P-CHLOROBENZOIC ACID, P-CHLOROHIPPURIC ACID, N-METHYL-P-CHLOROBENZAMIDE, 2-[N-METHYL-N-(P-CHLOROBENZOYL)]CARBAMOYLETHYLSULFONIC ACID, 3-SULFOPROPIONIC ACID & GLUCURONIDE OF P-CHLOROBENZOIC ACID.

MeSH Pharmacological Classification · 2 Einträge

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Absorption, Distribution and Excretion · 2 Einträge

RAPIDLY ABSORBED FROM GI TRACT...EFFECT WITHIN 15 TO 30 MIN...DURATION OF ACTION OF 4 TO 6 HR...FREE DRUG & /4-CHLOROHIPPURIC ACID/ EXCRETED IN URINE /HUMAN, ORAL/...PRESENT IN HIGH CONCN IN KIDNEY, LIVER, MUSCLE, HEART, & BODY FAT, & IN LESSER CONCN IN LUNG & PLASMA /RATS, ORAL/.

AFTER ORAL ADMIN OF (14)C-CHLORMEZANONE, ABOUT 74% OF DOSE WAS EXCRETED INTO URINE OF RATS WITHIN 24 HR & 21% INTO URINE OF MICE WITHIN 2 HR. BILIARY EXCRETION OF RADIOACTIVITY WAS ABOUT 10% OF DOSE IN RATS.

Verwendung und Herstellung

Uses · 2 Einträge

MEDICATION

Used in the management of anxiety and in the treatment of muscle spasm.

Methods of ManufacturingPREPN STARTING WITH 4-CHLOROBENZYLIDENEMETHYLAMINE: SURREY ET AL, J AM CHEM SOC 80, 3469 (1958): BRIT PAT 815,203 (1959 TO STERLING DRUG).
Formulations/PreparationsORAL: TABLETS 100 & 200 MG
Use ClassificationPharmaceuticals

Anwendungen

VerwendenChlormezanone improves the emotional state of the patient, relieving moderate anxiety and stress. However, it has a number of side effects, and because it does not have any advantage over other anxiolytics, it is rarely used in practice.

Vor- und nachgelagerte Produkte

Anbieter50 Anbieter

梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
阿诺西(上海)生物技术有限公司400-1107768 15058188853 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
上海麦克林生化科技股份有限公司021-50706066 15221275939 · [email protected]
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.

Zugehörige Reaktionen

0

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Verknüpfte Notizen

Wird geladen…